EP3016638A1 - Pharmaceutical composition comprising a solid dispersion of tadalafil - Google Patents

Pharmaceutical composition comprising a solid dispersion of tadalafil

Info

Publication number
EP3016638A1
EP3016638A1 EP14733663.0A EP14733663A EP3016638A1 EP 3016638 A1 EP3016638 A1 EP 3016638A1 EP 14733663 A EP14733663 A EP 14733663A EP 3016638 A1 EP3016638 A1 EP 3016638A1
Authority
EP
European Patent Office
Prior art keywords
tadalafil
composition according
process according
weight ratio
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14733663.0A
Other languages
German (de)
French (fr)
Inventor
Deepak Murpani
Manuel GAGO GUILLAN
Marta VIVANCOS MARTINEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Priority to EP14733663.0A priority Critical patent/EP3016638A1/en
Priority claimed from PCT/EP2014/063863 external-priority patent/WO2015000853A1/en
Publication of EP3016638A1 publication Critical patent/EP3016638A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • Tadalafil ((6R-trans)-6-(l,3-benzodioxol-5-yl)- 2,3 ,6,7,12, 12a-hexahydro-2-methyl- pyrazino [ ⁇ , 2':1,6] pyrido[3,4-b]indole-l ,4-dione) of formula (1)
  • ED erectile dysfunction
  • BPH benign prostatic hyperplasia
  • Cialis® erectile dysfunction
  • Adcirca® pulmonary arterial hypertension
  • the compound was discovered by ICOS and disclosed in W09519978.
  • Tadalafil is poorly soluble in water; therefore it needs to be formulated in such a way that the dissolution and bioavailability is improved.
  • W09638131 discloses solid dispersions in the form of co-precipitates of tadalafil with hydroxypropyl methylcellulose phthalate.
  • W09638131 discloses solid dispersions in the form of co-precipitates of tadalafil with hydroxypropyl methylcellulose phthalate.
  • W09638131 discloses solid dispersions in the form of co-precipitates of tadalafil with hydroxypropyl methylcellulose phthalate.
  • W09638131 discloses solid dispersions in the form of co-precipitates of tadalafil with hydroxypropyl methylcellulose phthalate.
  • WO0108688 discloses that a formulation comprising tadalafil milled to a particle size with d90 less than 10 microns has improved bioavailability. However, milling to such small particle sizes can result in reduced flowability, loss of active substance and can influence chemical and polymorphic stability of the active ingredient.
  • WO2008005039 discloses composites of tadalafil and water soluble polymers, prepared by dissolving tadalafil and a hydrophilic polymer in ethanol and subsequently spray drying the solution to obtain a powder that can be used to prepare a pharmaceutical formulation (no examples given of the pharmaceutical formulation). All examples given use large quantities of ethanol, about 1000 ml per gram tadalafil, which makes the process unsuitable for commercial scale.
  • WO2011012217 discloses formulations comprising a co-precipitate of tadalafil with an acrylate polymer with cationic character.
  • the co-precipitate is mixed with other excipients and compressed into tablets.
  • the process to prepare the co-precipitate is tedious, the co-precipitate needs to be dried at relatively high temperature (50°C) for a long period of time (20 hours), which may result in degradation of the active ingredient.
  • WO2012095151 discloses formulations prepared by fluid bed granulation using a solution of tadalafil and spraying it on a water insoluble polymer mixed with a diluent. It is necessary to perform the fluid bed granulation at high temperatures, which might increase levels of impurities. The obtained granulate is mixed with other excipients and compressed into tablets.
  • ethyl cellulose as water insoluble polymer, which is often used in extended release formulations and can negatively influence dissolution and hence
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a solid dispersion of tadalafil in a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, exhibiting a dissolution rate of at least about 85 wt% within 15 min when tested in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm.
  • the invention provides a process for preparing said pharmaceutical composition comprising the steps of:
  • step b granulating a suitable filler using the solution of step a;
  • Fig. 1 Dissolution profile of a pharmaceutical formulation in accordance with the present invention comprising a solid dispersion of amorphous tadalafil compared to the dissolution profile of Cialis ® 20 mg IR tablets in 1000 ml of aqueous 0.35 wt% SDS in a USP apparatus II at 50 rpm.
  • Fig. 2 XRPD of a granulate obtained by fluid bed granulation of tadalafil: Soluplus (weight ratio 1 :5) indicating tadalafil to be present in an amorphous form in said granulate
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a solid dispersion of tadalafil in a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, exhibiting a dissolution rate of at least about 85 wt% within 15 min when tested in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm.
  • solid dispersion a solid product consisting of a hydrophobic drug, i.e. tadalafil, and a hydrophilic matrix, i.e. the copolymer, in which the drug tadalafil is molecularly dispersed in said copolymer.
  • tadalafil is present in an amorphous form.
  • the weight ratio tadalafil: copolymer ranges from 1 :2 to 1 :8, preferably from 1 :3 to 1 :7, more preferably from 1 :4 to 1 :6, most preferred is a ratio of 1 :5.
  • a suitable polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer is marketed by BASF under the trade name Soluplus®.
  • the composition of the present invention additionally comprises a filler.
  • the filler to be used in accordance with the present invention may be any filler known to a person of ordinary skill in the art.
  • the filler to be used in accordance with the present invention is an inorganic filler, polysaccharide, mono-or disaccharide or sugar alcohol.
  • the filler used in accordance with the present invention is selected from the group consisting of microcrystalline cellulose, magnesium aluminometasilicate and starch. Microcrystalline cellulose is a particularly preferred filler.
  • the composition of the present invention additionally comprises a disintegrant.
  • the disintegrant to be used in accordance with the present invention may be any disintegrant known to a person of ordinary skill in the art. Suitable disintegrants to be used in accordance with the present invention are selected from the group consisting of croscarmellose,
  • Croscarmellose is a particularly preferred
  • the composition of the present invention additionally comprises a lubricant.
  • the lubricant to be used in accordance with the present invention may be any lubricant known to a person of ordinary skill in the art.
  • Magnesium stearate is a particularly preferred lubricant.
  • compositions of the present invention show no crystalline peaks (see e.g. Fig. 2), indicative of the absence of free (crystalline) tadalafil and indicative of an amorphous solid dispersion.
  • the pharmaceutical composition of the present invention displays dissolution behavior typical for immediate release formulations (see e.g. Fig. 1), without the need of using a micronized tadalafil as active pharmaceutical ingredient.
  • tadalafil is not present in the composition as particles, but it is molecularly dispersed in a hydrophilic matrix, which is the polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, wherein the interaction with the water soluble polymer contributes to the enhanced dissolution of tadalafil.
  • a hydrophilic matrix which is the polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, wherein the interaction with the water soluble polymer contributes to the enhanced dissolution of tadalafil.
  • the present invention further provides a process for preparing said pharmaceutical composition comprising a solid dispersion of tadalafil in a copolymer described above comprising the steps of:
  • step b granulating a suitable filler using the solution of step a;
  • the solvent or mixture of solvents to be used in accordance with the present invention may be any solvent or mixture of solvents known to a person of ordinary skill in the art. Importantly, both tadalafil and copolymer are completely dissolved.
  • the solvent used in accordance with the present invention may be a polar organic solvent while the mixture of solvents may be a mixture of polar organic solvents or a mixture of a polar organic solvent with water.
  • Suitable polar organic solvent to be used in accordance with the present invention include aprotic polar organic solvents selected from the group consisting of ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, acetonitrile, dimethylformamide, dimethyl sulfoxide, and acetone.
  • Particularly preferred aprotic polar organic solvents are tetrahydrofuran and acetone.
  • a particularly preferred mixture of an aprotic polar organic solvent with water is a mixture of acetone and water.
  • a mixture of acetone and water in a weight ratio of from about 8:2 to about 9:1 , more preferably a weight ratio of from 8.5:1.5 to 9:1.
  • lgram of tadalafil and 5 grams of copolymer (Soluplus) are dissolved in about 18 to 20 grams of the
  • Step a of the process in accordance with the present invention typically is performed at a temperature of from about 25 °C to about 50°C. In an advantageous variant of the invention process, step a is performed at a temperature of from about 40°C to about 50°C.
  • the process of the present invention is performed in a fluid bed granulator or a high sheer granulator, most preferably in a fluid bed granulator.
  • the process according to the present invention further comprises the steps of mixing the dried and optionally sieved granulate with a disintegrant, a lubricant, and optionally one or more additional pharmaceutically acceptable excipients, and compressing the mix into a tablet, using procedures and equipment well-known to a person skilled in the art.
  • the process of the present invention is advantageous as it avoids the use of large quantities of solvents and tedious communition procedures. Furthermore, the process of the invention requires short granulation times. For these reasons it is easy to perform the process of the invention on a commercial scale.
  • Soluplus and tadalafil are mixed and dissolved in acetone, or a mixture of acetone:water 9:1 and optionally heated to 50°C.
  • Microcrystalline cellulose is added to a high shear granulator equipped with double jacket heating and heated to 50-60°C.
  • the tadalafil / Soluplus solution is sprayed onto the microcrystalline cellulose for 1 minute in intervals of 2 minutes during granulation until the total amount of solution is added. Granulation is continued until a loss of drying of ⁇ 3%.
  • XRPD is measured of the obtained granules and no peaks indicative of crystalline tadalafil are observed.
  • the obtained granules are sieved through a 0.710 mm mesh sieve.
  • Disintegrant croscarmellose
  • lubricant magnesium stearate
  • the lubricated blend is compressed in an eccentric machine to get tablets of 480 mg and hardness of 60N.
  • the dissolution of the tablets is measured in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm, the tablets showed a dissolution rate of at least about 85 wt% within 15 min.
  • Soluplus and tadalafil were mixed and dissolved in an appropriate solvent (acetone, or a mixture of acetone:water, optionally heated to 50°C).
  • Microcrystalline cellulose was added to the fluid bed granulator.
  • the tadalafil/Soluplus solution was sprayed onto microcrystalline cellulose at 10-15 rpm. The process was performed with an inlet air temperature of 60°C. After addition of the solution, granulation was continued until a loss of drying of ⁇ 3%.
  • XRPD see Fig. 2) was measured of the obtained granules and no peaks indicative of crystalline tadalafil were observed.
  • the obtained granules were sieved through a 0.710 mm mesh sieve.
  • Disintegrant croscarmellose

Landscapes

  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a solid dispersion of tadalafil in a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer and a process to prepare said composition in a fluid bed granulator or a high shear granulator.

Description

PHARMACEUTICAL COMPOSITION COMPRISING A SOLID DISPERSION OF TADALAFIL
Tadalafil ((6R-trans)-6-(l,3-benzodioxol-5-yl)- 2,3 ,6,7,12, 12a-hexahydro-2-methyl- pyrazino [Γ, 2':1,6] pyrido[3,4-b]indole-l ,4-dione) of formula (1)
is a pharmaceutically active compound used for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) under the name Cialis® and, under the name Adcirca®, for the treatment of pulmonary arterial hypertension. The compound was discovered by ICOS and disclosed in W09519978. Tadalafil is poorly soluble in water; therefore it needs to be formulated in such a way that the dissolution and bioavailability is improved.
W09638131 discloses solid dispersions in the form of co-precipitates of tadalafil with hydroxypropyl methylcellulose phthalate. However, when measuring the dissolution of formulations prepared with these co-precipitates, we found that these were too low to expect a good bioavailability. Therefore, co-precipitation with hydroxypropyl methylcellulose phthalate is not a suitable method to increase the bioavailability of tadalafil.
WO0108688 discloses that a formulation comprising tadalafil milled to a particle size with d90 less than 10 microns has improved bioavailability. However, milling to such small particle sizes can result in reduced flowability, loss of active substance and can influence chemical and polymorphic stability of the active ingredient. WO2008005039 discloses composites of tadalafil and water soluble polymers, prepared by dissolving tadalafil and a hydrophilic polymer in ethanol and subsequently spray drying the solution to obtain a powder that can be used to prepare a pharmaceutical formulation (no examples given of the pharmaceutical formulation). All examples given use large quantities of ethanol, about 1000 ml per gram tadalafil, which makes the process unsuitable for commercial scale.
WO2011012217 discloses formulations comprising a co-precipitate of tadalafil with an acrylate polymer with cationic character. The co-precipitate is mixed with other excipients and compressed into tablets. The process to prepare the co-precipitate is tedious, the co-precipitate needs to be dried at relatively high temperature (50°C) for a long period of time (20 hours), which may result in degradation of the active ingredient.
WO2012095151 discloses formulations prepared by fluid bed granulation using a solution of tadalafil and spraying it on a water insoluble polymer mixed with a diluent. It is necessary to perform the fluid bed granulation at high temperatures, which might increase levels of impurities. The obtained granulate is mixed with other excipients and compressed into tablets. The examples mention the use of ethyl cellulose as water insoluble polymer, which is often used in extended release formulations and can negatively influence dissolution and hence
bioavailability.
In view of the cited prior art above there is a need of compositions comprising tadalafil and processes to prepare these compositions that do not have the disadvantages mentioned above.
BRIEF DESCRIPTION OF THE INVENTION The present invention provides a pharmaceutical composition comprising a solid dispersion of tadalafil in a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, exhibiting a dissolution rate of at least about 85 wt% within 15 min when tested in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm.
Additionally, the invention provides a process for preparing said pharmaceutical composition comprising the steps of:
a. dissolving tadalafil and a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer in a suitable solvent or mixture of solvents;
b. granulating a suitable filler using the solution of step a; and
c. drying the granulate.
BRIEF DESCRIPTION OF DRAWINGS
Fig. 1 Dissolution profile of a pharmaceutical formulation in accordance with the present invention comprising a solid dispersion of amorphous tadalafil compared to the dissolution profile of Cialis ® 20 mg IR tablets in 1000 ml of aqueous 0.35 wt% SDS in a USP apparatus II at 50 rpm.
Fig. 2 XRPD of a granulate obtained by fluid bed granulation of tadalafil: Soluplus (weight ratio 1 :5) indicating tadalafil to be present in an amorphous form in said granulate
DETAILED DESCRIPTION OF THE INVENTION
The following detailed description is provided so that the subject invention may be more fully understood by those skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the meaning as commonly understood by one of ordinary skill in the art.
The present invention relates to a pharmaceutical composition comprising a solid dispersion of tadalafil in a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, exhibiting a dissolution rate of at least about 85 wt% within 15 min when tested in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm.
In accordance with the present invention with the term "solid dispersion" is meant a solid product consisting of a hydrophobic drug, i.e. tadalafil, and a hydrophilic matrix, i.e. the copolymer, in which the drug tadalafil is molecularly dispersed in said copolymer. In said solid dispersion, tadalafil is present in an amorphous form.
The weight ratio tadalafil: copolymer ranges from 1 :2 to 1 :8, preferably from 1 :3 to 1 :7, more preferably from 1 :4 to 1 :6, most preferred is a ratio of 1 :5.
A suitable polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer is marketed by BASF under the trade name Soluplus®.
Preferably, the composition of the present invention additionally comprises a filler. The filler to be used in accordance with the present invention may be any filler known to a person of ordinary skill in the art. Particularly, the filler to be used in accordance with the present invention is an inorganic filler, polysaccharide, mono-or disaccharide or sugar alcohol. Advantageously, the filler used in accordance with the present invention is selected from the group consisting of microcrystalline cellulose, magnesium aluminometasilicate and starch. Microcrystalline cellulose is a particularly preferred filler.
Preferably, the composition of the present invention additionally comprises a disintegrant. The disintegrant to be used in accordance with the present invention may be any disintegrant known to a person of ordinary skill in the art. Suitable disintegrants to be used in accordance with the present invention are selected from the group consisting of croscarmellose,
crospovidone and sodium starch glycolate. Croscarmellose is a particularly preferred
disintegrant.
Preferably, the composition of the present invention additionally comprises a lubricant. The lubricant to be used in accordance with the present invention may be any lubricant known to a person of ordinary skill in the art. Magnesium stearate is a particularly preferred lubricant.
XRPD analysis experiments of the compositions of the present invention show no crystalline peaks (see e.g. Fig. 2), indicative of the absence of free (crystalline) tadalafil and indicative of an amorphous solid dispersion. The pharmaceutical composition of the present invention displays dissolution behavior typical for immediate release formulations (see e.g. Fig. 1), without the need of using a micronized tadalafil as active pharmaceutical ingredient. In the compositions of the present invention, tadalafil is not present in the composition as particles, but it is molecularly dispersed in a hydrophilic matrix, which is the polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, wherein the interaction with the water soluble polymer contributes to the enhanced dissolution of tadalafil.
The present invention further provides a process for preparing said pharmaceutical composition comprising a solid dispersion of tadalafil in a copolymer described above comprising the steps of:
a. dissolving tadalafil and a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer in a solvent or mixture of solvents;
b. granulating a suitable filler using the solution of step a; and
c. drying the granulate. The solvent or mixture of solvents to be used in accordance with the present invention may be any solvent or mixture of solvents known to a person of ordinary skill in the art. Importantly, both tadalafil and copolymer are completely dissolved.
Advantageously, the solvent used in accordance with the present invention may be a polar organic solvent while the mixture of solvents may be a mixture of polar organic solvents or a mixture of a polar organic solvent with water. Suitable polar organic solvent to be used in accordance with the present invention include aprotic polar organic solvents selected from the group consisting of ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, acetonitrile, dimethylformamide, dimethyl sulfoxide, and acetone. Particularly preferred aprotic polar organic solvents are tetrahydrofuran and acetone. A particularly preferred mixture of an aprotic polar organic solvent with water is a mixture of acetone and water.
Especially preferred is a mixture of acetone and water in a weight ratio of from about 8:2 to about 9:1 , more preferably a weight ratio of from 8.5:1.5 to 9:1. Typically, lgram of tadalafil and 5 grams of copolymer (Soluplus) are dissolved in about 18 to 20 grams of the
aforementioned solvent mixture.
Step a of the process in accordance with the present invention typically is performed at a temperature of from about 25 °C to about 50°C. In an advantageous variant of the invention process, step a is performed at a temperature of from about 40°C to about 50°C.
Preferably, the process of the present invention is performed in a fluid bed granulator or a high sheer granulator, most preferably in a fluid bed granulator.
Preferably, the process according to the present invention further comprises the steps of mixing the dried and optionally sieved granulate with a disintegrant, a lubricant, and optionally one or more additional pharmaceutically acceptable excipients, and compressing the mix into a tablet, using procedures and equipment well-known to a person skilled in the art.
The process of the present invention is advantageous as it avoids the use of large quantities of solvents and tedious communition procedures. Furthermore, the process of the invention requires short granulation times. For these reasons it is easy to perform the process of the invention on a commercial scale.
The following examples are intended to illustrate the scope of the present invention but not to limit it thereto.
EXAMPLES
Example 1
High shear granulation
Soluplus and tadalafil are mixed and dissolved in acetone, or a mixture of acetone:water 9:1 and optionally heated to 50°C. Microcrystalline cellulose is added to a high shear granulator equipped with double jacket heating and heated to 50-60°C. The tadalafil / Soluplus solution is sprayed onto the microcrystalline cellulose for 1 minute in intervals of 2 minutes during granulation until the total amount of solution is added. Granulation is continued until a loss of drying of < 3%. XRPD is measured of the obtained granules and no peaks indicative of crystalline tadalafil are observed. The obtained granules are sieved through a 0.710 mm mesh sieve. Disintegrant (croscarmellose) is mixed with the sieved granules for 15 min and finally, lubricant (magnesium stearate) is sieved through a 0.500 mm mesh sieve and mixed with the previous blend for 5 min. The lubricated blend is compressed in an eccentric machine to get tablets of 480 mg and hardness of 60N. The dissolution of the tablets is measured in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm, the tablets showed a dissolution rate of at least about 85 wt% within 15 min.
Example 2
Fluid bed process
Soluplus and tadalafil were mixed and dissolved in an appropriate solvent (acetone, or a mixture of acetone:water, optionally heated to 50°C). Microcrystalline cellulose was added to the fluid bed granulator. The tadalafil/Soluplus solution was sprayed onto microcrystalline cellulose at 10-15 rpm. The process was performed with an inlet air temperature of 60°C. After addition of the solution, granulation was continued until a loss of drying of < 3%. XRPD (see Fig. 2) was measured of the obtained granules and no peaks indicative of crystalline tadalafil were observed. The obtained granules were sieved through a 0.710 mm mesh sieve. Disintegrant (croscarmellose) was mixed with the sieved granules for 15 min and finally, lubricant
(magnesium stearate) was sieved through a 0.500 mm mesh sieve and mixed with the previous blend for 5 min. The lubricated blend was compressed in an eccentric machine to get tablets of 480 mg and hardness of 60N. The dissolution of the tablets (see Fig. 1) was measured in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm, the tablets showed a dissolution rate of 98 wt% within 15 min.

Claims

1. A pharmaceutical composition comprising a solid dispersion of tadalafil in a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer, exhibiting a dissolution rate of at least about 85 wt% within 15 min when tested in 1000 ml of aqueous medium containing 0.35 wt% SDS in a USP apparatus II at 50 rpm.
2. The composition according to claim 1 , wherein the weight ratio of tadalafil: copolymer ranges of from 1 :2 to 1 :8.
3. The composition according to claim 1 or 2, wherein the weight ratio of tadalafil:
copolymer ranges of from 1 :3 to 1 :7, preferably of from 1 :4 to 1 : 6.
4. The composition according to any one of claims 1 to 3, wherein the weight ratio tadalafil: copolymer is 1 :5.
5. The composition according to any one of claims 1 to 4, further comprising a filler.
6. The composition according to any one of claims 1 to 5, further comprising a disintegrant.
7. The composition according to any one of claims 1 to 6, further comprising a lubricant.
8. A process for preparing the composition according to any one of claims 1 to 7, comprising the steps of
a. dissolving tadalafil and a polyvinyl caprolactam - polyvinyl acetate - polyethylene glycol graft copolymer in a solvent or mixture of solvents;
b. granulating a filler using the solution of step a; and
c. drying the granulate.
9. The process according to claim 8, wherein the weight ratio of tadalafil: copolymer ranges of from 1 :2 to 1 :8.
10. The process according to claim 8 or 9, wherein the solvent is selected from the group consisting of ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, acetonitrile, dimethylformamide, dimethyl sulfoxide, and acetone.
11. The process according to any one of claims 8 to 10, wherein the solvent is acetone.
12. The process according to claim 8 or 9, wherein the mixture of solvents is a mixture of acetone and water in a weight ratio of from about 8:2 to about 9:1, preferably of from 8.5:1.5 to 9:1.
13. The process according to any one of claims 8 to 12, wherein the granulation is carried out in a fluid bed granulator or a high sheer granulator.
14. The process according to any one of claims 8 to 12, wherein step a is performed at a temperature of from about 25 °C to about 50°C.
15. The process according to any one of claims 8 to 14, further comprising the steps of
a. mixing the dried and optionally sieved granulate with a disintegrant, a lubricant and optionally one or more additional pharmaceutically acceptable excipients, and b. compressing the mix into a tablet.
EP14733663.0A 2013-07-05 2014-06-30 Pharmaceutical composition comprising a solid dispersion of tadalafil Withdrawn EP3016638A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14733663.0A EP3016638A1 (en) 2013-07-05 2014-06-30 Pharmaceutical composition comprising a solid dispersion of tadalafil

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2013064259 2013-07-05
EP14733663.0A EP3016638A1 (en) 2013-07-05 2014-06-30 Pharmaceutical composition comprising a solid dispersion of tadalafil
PCT/EP2014/063863 WO2015000853A1 (en) 2013-07-05 2014-06-30 Pharmaceutical composition comprising a solid dispersion of tadalafil

Publications (1)

Publication Number Publication Date
EP3016638A1 true EP3016638A1 (en) 2016-05-11

Family

ID=55637512

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14733663.0A Withdrawn EP3016638A1 (en) 2013-07-05 2014-06-30 Pharmaceutical composition comprising a solid dispersion of tadalafil

Country Status (1)

Country Link
EP (1) EP3016638A1 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2015000853A1 *

Similar Documents

Publication Publication Date Title
JP5443344B2 (en) Method for the manufacture of a drug containing tadalafil
CN100563658C (en) Solid dispersion or solid dispersion pharmaceutical preparation of phenylalanine derivative
WO2017108605A1 (en) Pharmaceutical composition comprising amorphous dasatinib
WO2013030789A1 (en) Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
WO2015001489A1 (en) Pharmaceutical compositions of ticagrelor
WO2014125352A1 (en) Pharmaceutical compositions comprising tadalafil
US10660963B2 (en) Pharmaceutical composition containing tacrolimus and preparation methods thereof
WO2014167579A2 (en) Stable pharmaceutical compositions of tadalafil
CN105358137A (en) Sovaprevir tablets
EP3601277B1 (en) Pharmaceutical formulation
CN103565763A (en) Dronedarone hydrochloride tablet and preparation method thereof
WO2015000853A1 (en) Pharmaceutical composition comprising a solid dispersion of tadalafil
EP2359816A1 (en) Aripiprazole formulations
US9561181B2 (en) Crystal forms
EP3731827A2 (en) Oral pharmaceutical composition comprising posaconazole
JP6231613B2 (en) Composition comprising an organic liquid diluent and a very low viscosity cellulose ether
EP3016638A1 (en) Pharmaceutical composition comprising a solid dispersion of tadalafil
WO2014095818A1 (en) Formulation comprising amorphous agomelatine
TW201700094A (en) Method of preparing very slightly soluble drug with solid dosage form
US20200093804A1 (en) Pharmaceutical composition of everolimus
HK40114208A (en) Crystal forms
RU2673228C2 (en) Pharmaceutical composition comprising a solid dispersion of tadalafil
WO2011010214A1 (en) Pharmaceutical composition of rifampicin
US20190202812A1 (en) Crystal Forms
CN104382840A (en) S-ambrisentan oral preparation composition and preparation method thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160830